Navigation Links
Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
Date:9/28/2011

GREENWOOD VILLAGE, Colo., Sept. 28, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has received notification of allowance of its two patent applications on Zertane™ combinations with erectile dysfunction (ED) drugs in Canada.  This allowance includes claims directed to the use of Zertane™ with a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors commonly used for the treatment of ED to address concurrent premature ejaculation (PE) and ED. The allowed claims also include composition of matter claims, such as claims directed to a pharmaceutical composition or a kit containing Zertane™ and a PDE5 inhibitor. Similar patent applications are being prosecuted worldwide.

It has been reported that ED and PE can co-exist in up to 30% of patients. There may be patients with ED who are effectively treated with phosphodiesterase type 5 inhibitors but who may have PE.  The patented combination of PE and ED drugs addresses this substantial group of patients.

"This first allowance of these two patents in Canada is an important milestone in Ampio's strategy to continue the development of its sexual dysfunction portfolio by first obtaining strong intellectual property protection," said Don Wingerter Ampio's CEO. "We are very excited by this development as we anticipate it will help increase our growing out-licensing activity for this product line," continued Don Wingerter.

About Zertane

The active ingredient in Zertane™ is a drug that was approved for marketing as a noncontrolled analgesic in 1995. In two Phase III clinical trials, Zertane™ has proven to be an effective oral medication to treat PE in men. Premature ejaculation is the most common form of male sexual dysfunction (four times the number with ED) with an estimated 23% of males suffering from this condition. The impact on the quality of life for these men and their partners can be profound. Behavioral therapy is the current standard of care for treatment of PE.

About Ampio

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, future intellectual property rights, successful commercialization and marketing of Zertane™ and combination drugs, successful licensing and partnering activity, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact: Investor Relations
Ampio Pharmaceuticals, Inc. 720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
2. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
3. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
4. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
5. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
6. Ampio Pharmaceuticals Set to Join Russell 3000 Index
7. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
8. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
9. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
10. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
11. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Summary GBI ... a Key Component of Multichannel Marketing" provides a ... in the digital age. While the pharmaceutical ... advancements, it has been much slower to adopt ... traditional channels and methods. However, the decreasing effectiveness ...
(Date:3/28/2017)... 2017  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... fourth quarter and year ended December 31, 2016. ... progress for Orexigen, beginning with the re-acquisition of the ... March, the team at Orexigen demonstrated remarkable focus, executing ... and strengthened our Company while rewarding us full control ...
(Date:3/28/2017)... and TORONTO , March 28, 2017 ... leading full service medical device development firm, announced today ... Toronto -based medical device industrial design ... serve medtech companies throughout North America ... experienced medical device talent spanning the design, engineering, regulatory, ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as it ... either don’t have access to a health care facility or a pharmacy within 60 minutes ... the United States or for many who are faced with health or personal issues that ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has ... to protect parental rights and civil liberties, and to restore transparency within government ... demonstration coincides with a press conference taking place Friday morning calling on President ...
(Date:3/28/2017)... ... , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts ... Secret. Dr. Wentz talked about journey and research recently on a blog and discussed ... the only solution to deal with thyroid disease. , Dr. Wentz completed her ...
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., a leading ... it has joined the National Association for Home Care and Hospice (NAHC), the ... and dying Americans of all ages and the caregiver who provide them with ...
Breaking Medicine News(10 mins):